Fort Worth, TX, United States of America

Charles Boring



 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2020-2024

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Charles Boring

Introduction

Charles Boring is an accomplished inventor based in Fort Worth, TX (US). He has made significant contributions to the field of pharmaceuticals, particularly in the formulation of high-concentration protein solutions. With a total of 2 patents to his name, Boring's work is recognized for its potential impact on patient care.

Latest Patents

Boring's latest patents focus on a stable protein solution formulation containing a high concentration of an anti-VEGF antibody. This invention provides anti-VEGF antibodies formulated as high-concentration, aqueous pharmaceutical compositions suitable for injection, preferably intravitreal injection. The aqueous pharmaceutical compositions are designed to deliver a high concentration of the antibody active ingredient to patients without high levels of antibody aggregation and without a significant level of sub-visible particulate matter. The composition includes an antibody with a concentration of at least 50 mg/ml, along with a sugar, a buffering agent, and a surfactant.

Career Highlights

Charles Boring is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on innovative solutions that enhance the efficacy of treatments in the pharmaceutical industry.

Collaborations

Boring has collaborated with notable colleagues such as Huixiang Zhang and Alok Kulshreshtha. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Charles Boring's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to improving patient outcomes. His work continues to influence the development of effective treatments in the healthcare sector.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…